Liberia LDEA: Ziankahn, Deputies Pass Drug Test Before Confirmation

• Newly appointed Liberia Drug Enforcement Agency (LDEA) Director General Daniel Dee Ziankahn, Jr. and his two deputies tested negative for drugs.
• The LDEA Senate confirmation drug screening occurred ahead of their Liberian Senate confirmation hearings.
• Ziankahn stated the testing demonstrates the new leadership's commitment to upholding the laws it enforces.
• Their appointment follows public criticism of the LDEA and the suspension of the former Officer-in-Charge amid cocaine seizures and investigations.
• The new Liberia Drug Enforcement Agency leadership is expected to strengthen the LDEA's anti-drug strategy, focusing on accountability and major trafficking networks.

He said the decision to undergo testing before their confirmation was intended to show that the new leadership is prepared to follow the laws it is expected to enforce.

Daniel Dee Ziankahn, Jr., the recently appointed Director General of the Liberia Drug Enforcement Agency (LDEA), along with his two deputies, Precious Rue for Operations and Prince Mulbah for Administration, recently underwent drug screening, with all three officials receiving negative results. This proactive measure took place on a Wednesday at the Wellness Health Center located in Congo Town, just outside Monrovia, and was observed by a team of journalists. The LDEA Senate confirmation drug screening is a significant step for the new leadership.

Following the test, Ziankahn articulated that individuals tasked with combating illicit drugs must first exemplify strong character and discipline, thereby setting a public standard. He said the decision to undergo testing before their confirmation was intended to show that the new leadership is prepared to follow the laws it is expected to enforce. This action underscores a foundational principle for the Liberia Drug Enforcement Agency leadership, as Ziankahn further stated, "As security officers, especially those fighting drugs, we need to lead the way and set the standards. As you can see here today, we came to do our drug test before going for confirmation."

The appointment of Daniel Dee Ziankahn Jr. and his deputies arrives at a critical juncture for the Liberia Drug Enforcement Agency, an institution that has recently faced considerable public scrutiny and doubts regarding its leadership and overall effectiveness in tackling drug trafficking. The agency's credibility had been challenged, leading to widespread concerns among the populace.

This leadership transition was precipitated by the indefinite suspension of Fitzgerald Biago, the former Officer-in-Charge. His suspension occurred amidst significant cocaine seizures and ongoing investigations that implicated the LDEA's previous administration. These events collectively fueled serious questions about accountability, internal discipline within the agency, and its fundamental capacity to effectively counter the illegal drug trade. In response to these pressing issues, President Joseph Nyuma Boakai formally appointed Ziankahn and his two deputies in an acting capacity, tasking them with overseeing the agency while the Senate confirmation process proceeds.

The Liberia Drug Enforcement Agency's comprehensive anti-drug strategy is structured around four core pillars: intelligence-led operations, drug prevention and demand reduction, institutional accountability and professionalism, and robust coordination with both national and international partners under the National Anti-Drug Action Plan. Intelligence-led operations aim to disrupt the supply of illicit drugs by enhancing border security, closely monitoring key entry points, and targeting the sophisticated trafficking networks that exploit Liberia as a transit route. The prevention and demand-reduction component focuses on public education, particularly for young people, through initiatives like school anti-drug clubs, community awareness campaigns, and providing treatment and rehabilitation programs.

Furthermore, the agency is committed to improving discipline and professionalism among its personnel through regular drug testing, comprehensive training, and a strict zero-tolerance policy for corruption and misconduct, reflecting key LDEA accountability initiatives. The fourth pillar emphasizes cooperation across various security institutions, health authorities, and communities to ensure a unified national response. Ziankahn has committed to actively pursuing these strategies and bolstering their implementation to enhance the LDEA's effectiveness, discipline, and professionalism. He has also called upon the agency's officers to maintain unwavering commitment, focus, and honesty in their duties, underscoring that the battle against drugs must originate with internal accountability.

Many Liberians harbor significant hope that Ziankahn's appointment will usher in meaningful changes for the LDEA, thereby rebuilding public trust in an institution vital for safeguarding the nation from illegal narcotics. Some observers believe his background in military and security affairs could be instrumental in fortifying discipline within the agency, refining its operational capabilities, and ensuring that officers involved in drug enforcement execute their responsibilities with utmost professionalism. There are also strong expectations that the new Liberia Drug Enforcement Agency leadership will shift its focus beyond merely apprehending street-level drug users, instead dedicating more attention and resources to major dealers, suppliers, and the extensive trafficking networks responsible for introducing illicit substances into the country. These Liberia anti-drug strategy changes are eagerly anticipated.

Lawyers advising clients in Liberia should anticipate a heightened focus on enforcement and institutional accountability from the Liberia Drug Enforcement Agency (LDEA) under its new leadership. This development signals a potential increase in scrutiny and a more stringent approach to drug-related offenses and compliance within the jurisdiction.

Source: Original reporting via Edwin G. Genoway, Jr.